thalidomide has been researched along with Cancer of the Fallopian Tube in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide has dual antiangiogenic and immunomodulatory properties and confirmed antitumor activity in hematologic malignancies." | 2.79 | A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. ( Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E, 2014) |
| "Thalidomide was not more effective than tamoxifen in delaying recurrence or death but was more toxic." | 2.75 | Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation ( Benbrook, DM; Brady, MF; Darcy, KM; Edmonds, P; Hurteau, JA; Ivanov, I; Mannel, RS; McGuire, WP; Pearl, ML; Tewari, KS; Zanotti, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Selle, F | 1 |
| Sevin, E | 1 |
| Ray-Coquard, I | 1 |
| Mari, V | 1 |
| Berton-Rigaud, D | 1 |
| Favier, L | 1 |
| Fabbro, M | 1 |
| Lesoin, A | 1 |
| Lortholary, A | 1 |
| Pujade-Lauraine, E | 1 |
| Hurteau, JA | 1 |
| Brady, MF | 1 |
| Darcy, KM | 1 |
| McGuire, WP | 1 |
| Edmonds, P | 1 |
| Pearl, ML | 1 |
| Ivanov, I | 1 |
| Tewari, KS | 1 |
| Mannel, RS | 1 |
| Zanotti, K | 1 |
| Benbrook, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Lipo[NCT01111903] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thalidomide and Cancer of the Fallopian Tube
| Article | Year |
|---|---|
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epit | 2014 |
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormo | 2010 |